COST-EFFECTIVENESS OF IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN ENGLAND

被引：0
|
作者：
Hassan, F. [1 ]
Peng, S. [2 ]
Dorman, E. [2 ]
Sorensen, S. [2 ]
Thompson, G. [1 ]
Lee, J. [1 ]
机构：
[1] Janssen UK, High Wycombe, Bucks, England
[2] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.246
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN163
引用
收藏
页码：A441 / A441
页数：1
相关论文
共 50 条
  • [21] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Odetola, Oluwatobi
    Ma, Shuo
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2023, 18 (05) : 130 - 143
  • [22] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Oluwatobi Odetola
    Shuo Ma
    Current Hematologic Malignancy Reports, 2023, 18 : 130 - 143
  • [23] Cost-effectiveness analysis of idelalisib-rituximab in relapsed or refractory CLL
    Marchetti, Monia
    Cuneo, Antonio
    Montillo, Marco
    Romana, Mauro Francesca
    Martelli, Elisa
    Pedone, Maria Paola
    LEUKEMIA & LYMPHOMA, 2015, 56 : 117 - 118
  • [24] The cost effectiveness of idelalisib in chronic lymphocytic leukaemia in England and Wales
    Sullivan, W.
    Hadlow, S.
    Perard, R.
    Mealing, S.
    Cox, L.
    Lee, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 92 - 93
  • [25] THE COST EFFECTIVENESS OF IDELALISIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA IN ENGLAND AND WALES
    Sullivan, W.
    Hadlow, S.
    Perard, R.
    Mealing, S.
    Cox, L.
    Lee, D.
    VALUE IN HEALTH, 2015, 18 (07) : A454 - A455
  • [26] COST-EFFECTIVENESS OF IBRUTINIB AS FRONTLINE TREATMENT FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN BELGIUM
    Smet, A.
    Peng, S.
    Dorman, E.
    Deger, K.
    Sorensen, S.
    Baculae, S.
    Cote, S.
    VALUE IN HEALTH, 2017, 20 (05) : A108 - A108
  • [27] Treatment of relapsed/refractory chronic lymphocytic leukaemia
    Ferrajoli, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 272 - 272
  • [28] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Brown, J. R.
    Eichhorst, B.
    Hillmen, P.
    Jurczak, W.
    Kazmierczak, M.
    Lamanna, N.
    O'Brien, S. M.
    Tam, C. S.
    Qiu, L.
    Zhou, K.
    Simkovic, M.
    Mayer, J.
    Gillespie-Twardy, A.
    Ferrajoli, A.
    Ganly, P. S.
    Weinkove, R.
    Grosicki, S.
    Mital, A.
    Robak, T.
    Osterborg, A.
    Yimer, H. A.
    Salmi, T.
    Wang, M. -D. -Y.
    Fu, L.
    Li, J.
    Wu, K.
    Cohen, A.
    Shadman, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04): : 319 - 332
  • [29] A COMPARISON OF THE APPRAISALS BY THE ENGLISH NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) FOR TWO THERAPIES FOR RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): IDELALISIB plus RITUXIMAB (IR) AND IBRUTINIB
    Thompson, G.
    Hassan, F.
    Lee, J.
    VALUE IN HEALTH, 2017, 20 (09) : A470 - A470
  • [30] COST-EFFECTIVENESS OF IDELALISIB PLUS RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKAEMIA
    Leleu, H.
    Blachier, M.
    Mealing, S.
    Perard, R.
    Baujat, C.
    Pentel, J.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
12345